Subtitle: Market Intelligence, Biological Rationale, and High-Purity Reagents for Mitochondrial Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PAM16 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAM16 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PAM16 Products |
| Gene Delivery | PAM16 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PAM16 Products |
| Benchmark Ab | Anti-PAM16 Control Antibody Recombinant positive control for assays. |
View PAM16 Products |
| Validator | PAM16 siRNA Set For knockdown verification. |
View PAM16 Products |
| Related Target A | PAM18 Direct interaction partner in the TIM23 complex. |
View PAM18 Products |
| Related Target B | TIM23 Core channel protein of the mitochondrial import machinery. |
View TIM23 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Disruption | High-purity PAM16 and PAM18 recombinant proteins (>95%) for accurate SPR/BLI binding assays. |
| Mitochondrial Localization Verification | Sequence Verified ORF clones ensuring native transit peptide sequences are intact. |
| Lack of Reliable Controls | Recombinant positive control antibodies included for western blot and IHC benchmarking. |
| Target Validation False Positives | Validated siRNA included for strict biological specificity checks in cell viability assays. |
Live PAM16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
PAM16 (also known as Magmas) is an emerging early-discovery target heavily implicated in mitochondrial protein import and cellular viability. Overexpressed in various malignancies, including glioblastoma and prostate cancer, it represents a critical vulnerability in cancer cell metabolism. The R&D landscape is currently focused on preclinical target validation, with researchers exploring small molecule inhibitors and RNA-targeting modalities designed to disrupt the PAM16-PAM18 interaction, thereby inducing apoptosis in targeted cancer cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Academic & Early Biotech | Solid Tumors (e.g., Glioblastoma) | PPI Disruption Assay (Need high-purity PAM16/PAM18 proteins) |
| RNAi / Antisense | Preclinical Validation | Oncology, Mitochondrial Dysfunction | Knockdown Validation (Need reliable siRNA sets) |
| Targeted Degradation (PROTACs) | Early Discovery | Refractory Cancers | Ternary Complex Validation (Need native conformation proteins) |